About Zinc finger protein 737
Zinc finger protein 737 (ZNF737) is a protein
from Homo sapiens identified by UniProt accession
O75373, 536 residues long.
MolForge cross-references it against 0 known binders and
9 disease associations.
Target properties
| Protein name | Zinc finger protein 737 |
| UniProt accession | O75373 |
| Gene | ZNF737 |
| Organism | Homo sapiens |
| Length | 536 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (9)
Diseases linked to this target (Open Targets).
- gut microbiome measurement · score 0.30
- hypertension · score 0.09
- heart failure · score 0.09
- response to xenobiotic stimulus · score 0.09
- Down syndrome · score 0.05
- prostate carcinoma · score 0.01
- Mental deterioration · score 0.00
- cancer · score 0.00
- cholelithiasis · score 0.00
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-O75373-F1 | alphafold | PREDICTED | 75.44 | — |
Amino-acid sequence (536 residues)
MGPLQFRDVA IEFSLEEWHC LDTAQRNLYR NVMLENYRNL VFLGIVVSKP DLITCLEQGK KPLTMKKHEM VANPSVTCSH FARDLWPEQS IKDSFQKVTL RRYENYGHDN LQFKKGCESV DECKVHKRGY NGLNQYLTTT QSKIFQCDKY VKVIHKFSNS NRHKIRHTGK KPFKCIECGK AFNQSSTLTT HKKIHTGEKP FKCEECGKAF NWSSHLTTHK RIHTGEKRYK CEDCGKAFSR FSYLTAHKII HSGEKPYKCE ECGKAFKRSS NLTTHKIIHT GEKPYKCEEC GKAFKRSSIL TAHKIIHSGE KPYKCEECGK AFKHPSVLTT HKRIHTGEKP YKCEECGRAF KYFSSLTTHK IIHSGEKPYK CEECGKAFNW SSHLTTHKRI HTGEKPYKCE ECGEAFKYSS SLTTHKIIHT GQQPFKCEEC GKAFKCFSIL TTHKRIHTGE KPYKCEECGK AFNSSSHLTA HKRIHTGEKP YKCERCGKAF KRSFILTRHK RIHTGEKPYK CEECGKGFKC PSTLTTHKVI HTGEKL
Explore Zinc finger protein 737 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets